CTOs on the Move

Slumber Sleep Aid

www.slumbercbn.com

 
Struggling with sleep issues? Try CBN for sleep! Slumber Sleep Aid offers variations of plant-based CBD and CBN products for sleep.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

CC Ford Group

CC Ford Group is a Bernardsville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humane Society for Southwest Washington

The Humane Society for Southwest Washington. Caring for animals in our community since 1897.

Cardiovascular Research Foundation

The Cardiovascular Research Foundation (CRF) in New York City is an independent, non-profit academic institution dedicated to improving the survival and quality of life of patients with cardiovascular disease through research and education.

Elizabeth R. Griffin Research Foundation

Elizabeth R. Griffin Research Foundation is a Kingsport, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.